- Details
- Description
-
Packaging Size60t/bottle
-
Strength5mg
-
CompositonAxitinib
-
TreatmentRenal cell carcinoma（RCC）
-
FormTablet
-
BrandLuciAxi
-
Quantity Unit5mg*60t/Box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Axitinib
Axitinib is a small molecule tyrosine kinase inhibitor. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types.
Renal Cell Carcinoma
Monotherapy
- Indicated for advanced renal cell carcinoma (RCC) in patients who failed 1 prior systemic therapy
- 5 mg PO BID initially
Combination therapy with avelumab
- Indicated in combination with avelumab for first-line treatment of advanced RCC
- Axitinib 5 mg PO BID, plus
- Avelumab 800 mg IV q2Weeks
- Continue until disease progression or unacceptable toxicity
- During combination therapy with avelumab, consider escalating dose of axitinib above 5 mg/dose in 2-week intervals or longer
- Refer the prescribing information of avelumab for dosing information
Combination therapy with pembrolizumab
- Indicated in combination with pembrolizumab for first-line treatment of advanced RCC
- Axitinib 5 mg PO BID, plus
- Pembrolizumab 200 mg IV q3Weeks or 400 mg IV q6Weeks
- Continue until disease progression or unacceptable toxicity
- During combination therapy with pembrolizumab, consider escalating dose of axitinib above 5 mg/dose in 6-week intervals or longer
- Refer the prescribing information of pembrolizumab for dosing information
